Advertisement

Annals of Surgical Oncology

, Volume 17, Issue 4, pp 967–972 | Cite as

TGM2 Is a Novel Marker for Prognosis and Therapeutic Target in Colorectal Cancer

  • Norikatsu Miyoshi
  • Hideshi Ishii
  • Koshi Mimori
  • Fumiaki Tanaka
  • Toshiki Hitora
  • Mitsuyoshi Tei
  • Mitsugu Sekimoto
  • Yuichiro Doki
  • Masaki Mori
Colorectal Cancer

Abstract

Background

Transglutaminase 2 (TGM2) plays a role in cell growth and survival through the antiapoptosis signaling pathway.

Methods

We analyzed TGM2 gene expression in 91 paired cases of colorectal cancer (CRC) and noncancerous regions and seven CRC cell lines to demonstrate the importance of TGM2 expression for the prediction of prognosis of CRC. TGM2 expression was higher in CRC tissue than in corresponding normal tissue by real-time reverse transcriptase–polymerase chain reaction (P = .015).

Results

Patients in the high TGM2 expression group showed a poorer overall survival rate than those in the low expression group (P = .001), indicating that the increase in TGM2 expression was an independent prognostic factor. TGM2 was also expressed in the seven CRC cell lines. The in vitro proliferation assay showed that TGM2 expression is involved with tumor growth.

Conclusions

The present study suggests that TGM2 is useful as a predictive marker for patient prognosis and may be a novel therapeutic target for CRC.

Keywords

Lymphatic Invasion High Expression Group Tumor Marker Carcinoembryonic Antigen TGM2 Expression Noncancerous Region 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

10434_2009_865_MOESM1_ESM.eps (651 kb)
Fig. S1 siRNA inhibition of TGM2 in 4 colorectal cancer cell lines. The suppression of TGM2 expression was confirmed by real-time reverse transcriptase–polymerase chain reaction, and the reduction was significant compared with NC (P < .05, Student’s t-test) in the 4 cell lines (A, HT-29; B, HCT116; C, KM12SM; D, LoVo). NC, negative control (eps 652 kb)

References

  1. 1.
    Kohno SI, Luo C, Nawa A, et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther. 2007;14:918–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Folk JE. Transglutaminases. Annu Rev Biochem. 1980;49:517–31.CrossRefPubMedGoogle Scholar
  3. 3.
    Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003;4:140–56.CrossRefPubMedGoogle Scholar
  4. 4.
    Antonyak MA, Singh US, Lee DA, et al. Effects of tissue transglutaminase on retinoic acid–induced cellular differentiation and protection against apoptosis. J Biol Chem. 2001;276:33582–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Boehm JE, Singh U, Combs C, et al. Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem. 2002;277:20127–30.CrossRefPubMedGoogle Scholar
  6. 6.
    Antonyak MA, Miller AM, Jansen JM, et al. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem. 2004;279:41461–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Mangala LS, Mehta K. Tissue transglutaminase (TG2) in cancer biology. Prog Exp Tumor Res. 2005;38:125–38.CrossRefPubMedGoogle Scholar
  8. 8.
    Mehta K. Mammalian transglutaminases: a family portrait. Prog Exp Tumor Res. 2005;38:1–18.CrossRefPubMedGoogle Scholar
  9. 9.
    Mann AP, Verma A, Sethi G, et al. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res. 2006;66:8788–95.CrossRefPubMedGoogle Scholar
  10. 10.
    Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th edn. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80:1803–4.Google Scholar
  11. 11.
    Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 1997;76:531–6.PubMedGoogle Scholar
  12. 12.
    Mori M, Staniunas RJ, Barnard GF, et al. The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology. 1993;105:820–6.PubMedGoogle Scholar
  13. 13.
    Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci. 2002;27:534–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int J Cancer. 1994;58:400–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Chen JS, Konopleva M, Andreeff M, et al. Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. J Cell Physiol. 2004;200:223–34.CrossRefPubMedGoogle Scholar
  16. 16.
    Mehta K, Fok J, Miller FR, et al. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res. 2004;10:8068–76.CrossRefPubMedGoogle Scholar
  17. 17.
    Herman JF, Mangala LS, Mehta K. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene. 2006;25:3049–58.CrossRefPubMedGoogle Scholar
  18. 18.
    Sarang Z, Molnar P, Nemeth T, et al. Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice. Hepatology. 2005;42:578–87.CrossRefPubMedGoogle Scholar
  19. 19.
    Aeschlimann D, Paulsson M. Transglutaminases: protein cross-linking enzymes in tissues and body fluids. Thromb Haemost. 1994;71:402–15.PubMedGoogle Scholar
  20. 20.
    Aeschlimann D, Koeller MK, Allen-Hoffmann BL, Mosher DF. Isolation of a cDNA encoding a novel member of the transglutaminase gene family from human keratinocytes. Detection and identification of transglutaminase gene products based on reverse transcription–polymerase chain reaction with degenerate primers. J Biol Chem. 1998;273:3452–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Chen JS, Mehta K. Tissue transglutaminase: an enzyme with a split personality. Int J Biochem Cell Biol. 1999;31:817–36.CrossRefPubMedGoogle Scholar
  22. 22.
    Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991;5:3071–7.PubMedGoogle Scholar
  23. 23.
    Ai L, Kim WJ, Demircan B, et al. The transglutaminase 2 gene (TGM2.), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis. 2008;29:510–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Andre T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;25:3732–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296–10.CrossRefPubMedGoogle Scholar
  26. 26.
    Kornmann M, Formentini A, Ette C, et al. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol. 2008;34:1316–21.PubMedGoogle Scholar
  27. 27.
    Bathe OF, Dowden S, Sutherland F, et al. 2004 Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 4:32.CrossRefPubMedGoogle Scholar
  28. 28.
    Lacy AM, Garcia-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2002;359:2224–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Weeks JC, Nelson H, Gelber S, et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 2002;287:321–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Group COoSTS. 2004 A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 350:2050–9.CrossRefGoogle Scholar
  31. 31.
    Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25:3061–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Han JA, Park SC. Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol. 1999;125:89–95.CrossRefPubMedGoogle Scholar
  33. 33.
    Devarajan E, Chen J, Multani AS, et al. Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int J Oncol. 2002;20:913–20.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Norikatsu Miyoshi
    • 1
  • Hideshi Ishii
    • 1
    • 2
  • Koshi Mimori
    • 2
  • Fumiaki Tanaka
    • 2
  • Toshiki Hitora
    • 1
  • Mitsuyoshi Tei
    • 1
  • Mitsugu Sekimoto
    • 1
  • Yuichiro Doki
    • 1
  • Masaki Mori
    • 1
  1. 1.Department of Gastroenterological SurgeryOsaka University Graduate School of MedicineOsakaJapan
  2. 2.Division of Molecular and Surgical Oncology, Department of Molecular and Cellular Biology, Medical Institute of BioregulationKyushu UniversityOhitaJapan

Personalised recommendations